Piramal Pharma Ltd — Feb 2025 Quarterly Analysis

1. VERDICT & BUSINESS QUALITY SNAPSHOT

Result: Inline **One-line:** The thesis remains on track as high-teens CDMO growth and volume expansion in Complex Hospital Generics (CHG) offset persistent structural tax leakage and seasonal PAT volatility.

Dimension	This Quarter	Signal / Evidence	Sentiment
Beat/Miss vs Guidance	Inline	9M Revenue/EBITDA growth (14%/20%) tracks ahead of "early teens" guidance, leaving room for a strong Q4.	□
Earnings Quality	Moderate	EBITDA is core-driven, but PAT remains deep in the red (□83 Cr loss) due to □120 Cr+ tax incident on loss-making subsidiaries.	□
Guidance Confidence	Strong	Management reiterated FY25 guidance and FY30 targets ($2Bn+ Rev, 25% Margin) with high conviction.	□
Management Credibility	Strong	Executed on ESG (biomass boiler), new product launches (16 in 9M), and key leadership hiring (New ICH CEO).	□
Business Quality Signal	Improving	CDMO mix continues to shift toward "on-patent commercial," providing higher margin stability and stickier revenue.	□
Key Q&A Exchange	Q#4, 5 & 10 (Biotech Funding)	Management admits biotech funding is for "replenishment, not acceleration," tempering the Biosecure Act hype.	□
The Street's Primary Anxiety	Structural Tax Leakage	Analysts pressed on 100%+ ETR; Mgmt expects a drop in Q4 but provides no structural fix for inter-subsidiary offsets.	□
Capital Cycle Stage	Growth / Investment	Investing in Digwal/Dahej capacity for Sevoflurane and specialized CDMO assets (ADCs).	□
Margin Trajectory	Stable	Q3 Margin (16%) dipped YoY (17%) but 9M Margin (15%) is stable; Q4 operating leverage is the key lever.	□
Pricing Power	Mixed	Strong in niche Baclofen (70% share); Sevoflurane renewed at "peak tenders," but generic API remains competitive.	□
FCF Conversion	Distorted	Net Debt/EBITDA at 2.8x; Net debt remains elevated due to inventory stocking for seasonally heavy Q4.	□
Competitive Moat	Widening	#1 US share in Sevoflurane (40%+) and Baclofen (70%) plus "Scientific Collective" branding in CDMO.	□
Balance Sheet Strength	Adequate	Net Debt/EBITDA improved to 2.8x (from 3.0x in Q2); Net debt ~□4,200 Cr range.	□
Working Capital Efficiency	Seasonal	Typical H2 build-up; Management expects standard liquidation in Q4.	□
Mgmt Guidance Record	Reliable	Consistent delivery on segment-level growth targets across last 4 quarters.	□
Key Vulnerability	Geo-Political / Tax	Exposure to US administration policy on onshoring and inability to offset global losses against India profits.	□
Management Tone	Cautiously Optimistic	Strong confidence in execution but wary of "prolonged decision making" by CDMO clients.	□

Key Takeaways (Positives & Negatives): * **Positives:** The CDMO segment (57% of Rev) delivered 18% 9M growth, heavily skewed toward high-value innovation work. CHG volumes in Inhalation Anesthesia (IA) are robust, with a successful renewal of peak US tenders for Sevoflurane. ICH Power Brands (Little's, CIR, Polycrol) grew 26% (ex-price-controlled i-range), and e-commerce now contributes a significant 20% of sales. * **Negatives:** The P&L is still "leaky"—a □353 Cr EBITDA resulted in a □83 Cr Net Loss due to a □120 Cr tax expense (implied ETR >100% on PBT). While EBITDA margins are expanding on a 9M basis, the Q3 YoY dip (16% vs 17%) suggests one-off costs and unfavorable mix during the quarter. * **Street Concern:** The divergence between operational success (revenue/EBITDA) and shareholder returns (PAT/ROE) due to tax jurisdiction mismatches. Management's response—that Q4 will see "meaningful reduction" in ETR—is a short-term patch for a long-term structural efficiency problem. * **Forward Watchpoint:** Monitor the commercialization of Digwal/Dahej capacity in FY26. This is critical for moving CHG production to low-cost Indian sites to structurally re-rate segment margins.

---

2. BUSINESS PERFORMANCE

2A. KEY METRICS *Note: Q3FY25 vs Q3FY24 (YoY) is the primary comparison due to significant seasonality (Q4 heavy).*

Metric	Q3FY25	YoY Change	QoQ Change	Trend	Mgmt Commentary
Revenue (Consol)	□2,204 Cr	↑ 13%	↓ 1.7%	→	9M growth at 14%; Q3 slight QoQ dip due to CDMO lumpy ordering.
Revenue - CDMO	□1,278 Cr	↑ 13%	↓ 3.5%	→	Driven by on-patent commercial manufacturing and generic API recovery.
Revenue - CHG	□688 Cr	↑ 14%	↓ 6.0%	↑	Volume uptick in US IA; Sevoflurane #1 rank (40% share) maintained.
Revenue - ICH	□238 Cr	↑ 10%	↑ 28.0%	↑	Strong Power Brand growth (19%); E-commerce up 40% YoY.
EBITDA	□353 Cr	↑ 6%	↓ 12.6%	□	Growth tempered by □16.5 Cr ($2M) one-off spend in CHG.
EBITDA Margin %	16.0%	↓ 100 bps	↓ 200 bps	↓	YoY dip due to one-off costs and mix; 9M margin stable at 15%.
PAT (Net Loss)	□(83) Cr	↓ 34%	↓ NM	↓	Weighted by high ETR; profit in tax-paying sites, losses elsewhere.
Net Debt	~□4,200 Cr	→	→	→	Net Debt to EBITDA at 2.8x (vs 2.8x in Q2).
Interest Coverage	~2.3x	↓	↓	↓	High interest costs (□150 Cr range) persist.
R&D Pipeline (CHG)	24 products	→	→	→	Focus on 505(b)(2) and complex generics.

2B. SEGMENT BREAKDOWN

Segment	Revenue (□ Cr)	YoY Growth	Margin	Trend	vs Co. Avg	Key Development
CDMO	1,278	13%	~18-20%	↑	Above	Innovation-related work driving margin expansion.
CHG	688	14%	~12-14%	→	Below	Capacity expansion at Digwal/Dahej on track for FY26.
ICH	238	10%	Improving	↑	Below	Sai Ramana Ponugoti (ex-P&G) onboarded as CEO.

3. MANAGEMENT OUTLOOK & EXECUTION TRACKER

Dimension	Category	Management Target / Claim	Required Run-Rate / Mathematical Feasibility	Historical Delivery	Risk Flag
Guidance	Revenue	Early teens growth for FY25.	Needs ~□2,600 Cr in Q4 (~10% YoY). Very feasible given Q4 seasonality.	Met	Low
Guidance	Margins	25% EBITDA Margin by FY30.	Needs 100-150 bps annual expansion. Currently at 15% (9M).	Improving	Moderate
Guidance	PAT	"Meaningful improvement" in FY25.	Needs a blockbuster Q4 (□150 Cr+ PAT) to turn 9M (□22 Cr) into significant growth.	Mixed	High
Strategy	ESG	42% GHG reduction by 2030.	17% reduction achieved via Digwal biomass boiler transition.	New	Low
Strategy	CHG Expansion	Next FY benefit from Digwal/Dahej.	Facilities completed; products on stability testing for FY26 launch.	In-Progress	Moderate
Macro	CDMO Demand	Biosecure Act Diversification.	Inquiries/RFPs up; PO conversion remains "prolonged."	In-Progress	Moderate

4. ANALYST Q&A

Q#	Relevance	Analyst	Theme Cluster	Category	Underlying Concern	Management Response & Investment Implication	Evaded	Credibility	Verdict
1	4.5	Amey Chalke / JM Financial	CDMO Mix	Financials	"Division between development and commercial CDMO growth?"	Growth is primarily from the commercial side as development remains subdued due to the biotech funding crisis and slow decision-making. Investors should expect CDMO margins to benefit from commercial scale-up while development remains a long-term optionality play.	None	4.0	Clear segment color
2	4.0	Sudarshan / Axis Capital	Taxation	Financials	"Why 100%+ effective tax rate and when will it drop?"	Management attributed the high ETR to profit/loss jurisdiction mismatches and expects a "meaningful reduction" in Q4 as other sites turn profitable. Structural PAT leakage remains the biggest risk to the P&L until global subsidiaries are consistently profitable.	None	3.5	Seasonal fix only
3	3.5	Sudarshan / Axis Capital	One-offs	Financials	"Status of one-off spend in CHG?"	Approximately $2M was spent in Q3, with the remaining	None	5.0	Specific quantification

Q#	Relevance	Analyst	Theme Cluster	Category	Underlying Concern	Management Response & Investment Implication	Evaded	Credibility	Verdict
						$2M expected in Q4. This implies a ~₹16 Cr quarterly headwind to margins that will disappear in FY26.			
4	4.0	Abdulkader / ICICI Sec	Cost Optimization	Financials	"Strategic initiatives for margin expansion?"	Management is in year 3 of procurement and operational effectiveness programs covering labor and materials. These efforts are the primary drivers of the 9M EBITDA growth (20%) outstripping revenue growth (14%).	None	4.0	Operational evidence
5	3.5	Abdulkader / ICICI Sec	CHG Contracts	Business Overview	"Impact of new contracts on CHG growth?"	Growth was driven by renewals of existing US peak tenders (stability) and new ex-US contracts. Consistent volume growth in Sevoflurane validates the global expansion strategy beyond the US.	None	3.0	Directional
6	4.0	Tushar M / Motilal	Biotech Funding	Macro	"What is holding back biotech funding besides	Factors include M&A exit clarity, US policy shifts under the new cabinet,	None	3.0	Macro realism

Q#	Relevance	Analyst	Theme Cluster	Category	Underlying Concern	Management Response & Investment Implication	Evaded	Credibility	Verdict
					interest rates?"	and pending IPO queues. The CDMO recovery is likely to be "cautiously optimistic" rather than a sharp V-shaped rebound.			
7	4.0	Madhav M / FIL	CHG Site	Capex and Allocation	"Status of Digwal/ Dahej for RoW markets?"	Digwal is completed and on stability; Dahej is progressing for next fiscal year benefits. This shift to Indian manufacturing is the central lever for CHG's long-term 25% margin target.	None	5.0	Specific timeline
8	3.5	Vilas Jain	Seasonality	Financials	"Why the huge skew toward Q4?"	Management cited customer ordering patterns and fixed cost leverage as the primary reasons for Q4 being the "make or break" quarter. Seasonality remains a structural feature, not a bug, of the PPL business model.	None	3.0	Structural reality
9	4.0	Alankar / Kotak	Biosecure Act	Macro	"Potential slowdown in RFPs due to	Management noted they have available	None	4.0	Competitive positioning

Q#	Relevance	Analyst	Theme Cluster	Category	Underlying Concern	Management Response & Investment Implication	Evaded	Credibility	Verdict
					Biosecure uncertainty?"	capacity in the US and "front-shoring" countries (India, UK) to capture diversification demand. PPL is positioned as a primary beneficiary if China-de-risking accelerates.			
10	4.5	Sajal Kapoor	CDMO Economics	Business Overview	"Greenfield US vs India API facility economics?"	Management is not contemplating US greenfield API; they will leverage existing US capacity for high-value on-patent work and India for volume. This hybrid global-delivery model protects margins from potential US protectionist tariffs.	None	4.5	Strategic clarity

PATTERN FLAGS & SENTIMENT * **The Biotech Funding "Reality Check":** Multiple analysts (Amey, Tushar) probed the biotech environment. Management's tone was sober, noting that current funding levels are barely keeping biotechs afloat ("replacement level") rather than fueling a new R&D boom. This suggests that while Biosecure Act inquiries are high, PO conversion will be a multi-quarter slog. * **The Structural Tax Drag:** The persistent 100%+ ETR is the primary friction point between management and the Street. Analysts are frustrated by the PAT-level losses despite healthy EBITDA. Management's response—attributing it to geographic mismatches—confirms that until US/UK sites reach higher utilization, the P&L will remain inefficient. * **Analyst Sentiment Verdict:** Analysts were **satisfied with operational execution** (CDMO growth, CHG volumes) but **skeptical of the bottom-line turnaround**. Management's credibility on cost-cutting and ESG is high, but they are yet to convince the market that the tax leakage can be structurally plugged. The tone of the call was professional but focused on "waiting for Q4" to see the true earnings power.

GUIDANCE GAPS REVEALED IN Q&A | Topic | What Mgmt Claimed (Opening) | What Q&A Revealed | Gap / Walk-back | Risk to Thesis | | :--- | :--- | :--- | :--- | :--- | | CDMO Growth | Robust growth | Decision-making is "prolonged" | High inquiries ≠ Immediate POs | Moderate (Timing risk) | | Tax Rate | Not in opening | 100%+ in

Q3; drop in Q4 | Structural jurisdictional mismatch | High (PAT impact) | | ICH Growth | 10% Growth | i-range hit by price control | Core Power Brand growth is much higher (26%) | Low (Regulatory) |

5. WHAT CHANGED vs PRIOR QUARTER

What Changed	Prior Quarter (Q2FY25)	This Quarter (Q3FY25)	Direction
Revenue Momentum	17% YoY Growth	13% YoY Growth	↓ (Slight deceleration)
EBITDA Margin	18%	16%	↓ (YoY & QoQ compression)
Tax Rate (ETR)	54%	>100% (Implied)	↓ (Deteriorating)
Management Team	Evaluating ICH leadership	Onboarded Sai Ramana Ponugoti (CEO-ICH)	↑ (Credibility boost)
ESG Roadmap	Commitment stage	17% total emission reduction via Biomass Boiler	↑ (Tangible execution)
CHG One-offs	$4M spend initiated	$2M spent; $2M remaining for Q4	→ (Quantified)
CDMO Demand	"Materially higher" RFPs	Inquiries high; decision making "prolonged"	□(Tempered timeline)
Net Profit	□23 Cr Profit	□(83) Cr Loss	↓ (Deteriorating)

- **Earnings Quality Lever:** The divergence between the □353 Cr EBITDA and the □83 Cr Net Loss is entirely driven by the **Tax Expense (□120 Cr)** and **Interest (□153 Cr)**. Working capital build-up in inventory for Q4 also contributed to higher interest costs, creating a "leaky" P&L that masks strong operational volumes.